LIFE TRIAL
Problem Hypertension, LVH
Format Double-blinded multi-center RCT
Treatment Losartan
Control Atenolol
Population 9193
Inclusion criteria Men and women 55-80
Previously untreated hypertension
LVH on ECG
Exclusion criteria Known secondary hypertension
Increase of SBP > 200 or DBP > 115 in placebo period
Stroke/MI in last 6 months
Angina requiring beta-blocker or calcium-channel blocker
HF or LVEF <= 40%
Creatinine > 160 or solitary kidney
Aortic stenosis with gradient > 20 mmHg
Other requirements of/contraindications to therapy
Follow-up Mean 4.7 years
Primary endpoint Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)
Secondary endpoint(s) Cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus
Details .
Brief summary: Losartan reduced mortality above atenolol for same BP reduction
PAPER: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Date 23 Mar 2002
Journal Lancet. 2002 Mar 23;359(9311):995-1003.
Information Losartan (vs Atenolol) in HTN and LVH
-Great reduction in cardiovascular morbidity and death than atenolol
-Similar reduction in blood pressure
-Better tolerated
-Seems to confer benefits beyond reduction in blood pressure
PAPER: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Date 23 Mar 2002
Journal Lancet. 2002 Mar 23;359(9311):1004-10.
Information Losartan (vs Atenolol), in those with HTN, DM, LVH
-More effective in reducing
--Cardiovascular morbidity and mortality
--All cause mortality
-Seems to have benefits beyond blood pressure reduction.
RSS  Subscribe: Latest / All - Designed by Dr James P Howard (Google+)